Clinical Research Directory

Inclusion Criteria: 1. voluntary participation in clinical research; Fully understand and Informed the study and sign the Informed Consent Form (ICF); Be willing to follow and be able to complete all trial procedures; 2. age of 18-75 years old (including boundary value), regardless of gender; 3. Pathologically confirmed locally advanced, metastatic non-small cell lung cancer (NSCLC), including squamous non-small cell lung cancer and non-squamous non-small cell lung cancer. Patients with non-squamous non-small cell lung cancer should exclude known EGFR mutation or ALK gene rearrangement. 4. patients with resistance to first-line PD-(L)1 inhibitors combined with chemotherapy; 5. patients with tumor response of CR/PR/SD after at least one first-line immunotherapy; 6. Subjects' ECOG PS score was 0-1 (including boundary value); 7. Patients had to have ≥1 measurable lesion (according to RECIST1.1 criteria). 8. predicted survival time ≥6 months; Exclusion Criteria: 1. Frontline treatment with anlotinib, anti-angiogenic macromolecular monoclonal antibody or other small molecule TKI drugs; 2. central lung cancer with large blood vessel invasion; 3. patients with any signs or history of bleeding that may affect treatment according to the investigator's judgment; Patients with bleeding events ≥CTCAE grade 3, unhealed wounds, ulcers, or fractures within 4 weeks before the first dose of study drug; 4. hemoptysis \> 50ml/d; 5. inability to swallow capsules or diseases that significantly affect gastrointestinal function, such as malabsorption syndrome, gastric or small bowel resection, bariatric surgery, inflammatory bowel disease, partial or complete intestinal obstruction; 6. Poorly controlled hypertension (defined as systolic blood pressure \>150 mmHg and/or diastolic blood pressure \>100 mmHg) 7. other known malignant tumors that are developing or require active treatment; 8. Currently participating or has participated in the clinical research of other drugs; 9. interstitial lung disease or (non-infectious) pneumonia requiring steroid therapy